CBS 2019
CBSMD教育中心
English

DAPT Duration

科研文章

荐读文献

State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting - A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation
|<< 1 2 3 4 5 6 7 ...>>|

JOURNAL：CBS2017 Article Link

向世界发出中国心声——TCT2017系列报道一

CBS2017


美国丹佛——当地时间10月29日上午11时00到11时30分， Peter Block医生在TCT（经导管心血管治疗学术会议）的举办地Colorado Convention Center， ACCEL办公室对远赴重洋，来自中国的DK Crush系列研究负责人陈绍良教授进行了一次深入的专访。此次访问紧密围绕DKCRUSH-V 对治疗冠脉左主干动脉真性远端分叉病变的双对吻挤压技术 (the double kissing crush techniques)与单支架技术(provisional side branch stenting)这一大规模多中心临床随机对照试验展开。






介入器械的日趋成熟并未彻底攻克冠脉分叉病变这一心血管重大疾病难点，不同的治疗策略亟需高信度、高水平的试验设计进行比较，并进一步接受全球临床的实战检验。为此，陈绍良团队历时十载，一直致力于此，持之以恒地探索治疗左主干分叉病变的可靠疗法，期待我国的创新可以为全球病患带去福音。






TCT2017重要日程预告



TCT2017作为冠脉左主干病变处理、生物可吸收支架、经导管瓣膜病治疗领域的顶尖专业盛会，将汇集12项最新揭晓临床试验（LBCTs）和16项首次报道研究（FRIs）结果在本次大会上揭晓。南京市第一医院陈绍良教授团队的DKCRUSH-V研究作为最值得关注的成果之一，将于当地时间10月30日11时40分（北京时间11月1日凌晨1点40分）在TCT2017主会场发布。南京市第一医院将分别于当地时间11月1日上午8时在主会场和10:00在冠脉分会场进行前后两次手术转播，分别演示经皮肺动脉去交感神经术（PADN）治疗原发性肺动脉高压、双对吻挤压术治疗左主干末端分叉病变技术，两场手术均由陈绍良教授担任主要术者。





>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top